Avalo Therapeutics, Inc. SEC filings AVTX
Avalo Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 9, 2017. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 28, 2026 | — |
| EFFECT | Filing | Jan 20, 2026 | — |
| CORRESP | Letter to the SEC | Jan 15, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2024 | — |
| EFFECT | Filing | Aug 5, 2024 | — |
| CORRESP | Letter to the SEC | Aug 1, 2024 | — |
| CORRESP | Letter to the SEC | Jul 29, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2024 | — |
| CORRESP | Letter to the SEC | Jul 11, 2024 | — |
| CORRESP | Letter to the SEC | Jul 11, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| D | Filing | Apr 9, 2024 | — |
| EFFECT | Filing | May 2, 2023 | — |
| CORRESP | Letter to the SEC | Apr 28, 2023 | — |
| EFFECT | Filing | Apr 27, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2023 | — |
| EFFECT | Filing | Mar 19, 2021 | — |
| CORRESP | Letter to the SEC | Mar 18, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2021 | — |
| CT ORDER | Filing | Sep 9, 2020 | — |
| EFFECT | Filing | May 18, 2020 | — |
| CORRESP | Letter to the SEC | May 14, 2020 | — |
| UPLOAD | Letter from the SEC | May 13, 2020 | — |
| EFFECT | Filing | Dec 31, 2019 | — |
| CORRESP | Letter to the SEC | Dec 30, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2019 | — |
| 425 | 8-k | Dec 23, 2019 | — |
| 425 | 8-k/a | Dec 11, 2019 | — |
| 425 | 8-k | Dec 5, 2019 | — |
| EFFECT | Filing | Oct 24, 2019 | — |
| CORRESP | Letter to the SEC | Oct 22, 2019 | — |
| CORRESP | Letter to the SEC | Oct 18, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2019 | — |
| CT ORDER | Filing | Apr 23, 2019 | — |
| EFFECT | Filing | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2019 | — |
| CORRESP | Letter to the SEC | Feb 7, 2019 | — |
| 25-NSE | Delisting notice | Oct 17, 2018 | — |
| EFFECT | Filing | Oct 5, 2018 | — |
| CORRESP | Letter to the SEC | Oct 3, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 21, 2018 | — |
| CORRESP | Letter to the SEC | Jul 27, 2018 | — |
| CORRESP | Letter to the SEC | Jun 22, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2018 | — |
| CT ORDER | Filing | Jun 14, 2018 | — |
| CORRESP | Letter to the SEC | May 25, 2018 | — |
| UPLOAD | Letter from the SEC | May 14, 2018 | — |
| EFFECT | Filing | Jun 9, 2017 | — |
| CORRESP | Letter to the SEC | Jun 7, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2017 | — |
| DEFR14A | Def 14a | May 23, 2017 | — |
| UPLOAD | Letter from the SEC | May 22, 2017 | — |
| PRER14A | Pre 14a | May 19, 2017 | — |
| CORRESP | Letter to the SEC | May 19, 2017 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534120
- Former names
- Cerecor Inc. (until Aug 18, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.